Yüklüyor......
Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity
Although the sodium channel blocker, mexiletine, is the first choice drug in myotonia, some myotonic patients remain unsatisfied due to contraindications, lack of tolerability, or incomplete response. More therapeutic options are thus needed for myotonic patients, which require clinical trials based...
Kaydedildi:
| Yayımlandı: | Neuropharmacology |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Pergamon Press
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5154332/ https://ncbi.nlm.nih.gov/pubmed/27743929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2016.10.013 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|